Business Update
Drug developer announces obesity-therapy patents and a $500,000 private equity investment
Published in Obesity and Diabetes Week, March 6th, 2006
The inhibition of fatty acid synthase as a means to control obesity has been a cornerstone of FASgen's extensive research into therapeutics to treat obesity. In parallel, the company also announced the award and issuance of its Eurasian patent, "Stimulation of CPT-1 as a Means to Reduce Weight." Stimulation of CPT-1 has been demonstrated to regulate fatty acid oxidation and the consequent weight loss that follows. FASgen's compounds have been shown to work at both the...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
More Articles from Obesity and Diabetes Week
- Diabetes Therapy
LAGB prevents diabetes and arterial hypertension and induces their remission in morbid obesity - Diet & Nutrition
Effects of vanadate on glucose production discussed - Drug Development
Novel tetrapeptide may provide therapeutic target for obesity and diabetes mellitus - Medical Devices
Actical accelerometer is a valid tool for measuring physical activity in children - Obesity Pathogenesis
CCR2 modulates inflammatory and metabolic effects of high-fat feeding - Alcohol Use
AA-AGE cytotoxicity is important in alcoholic-induced neuronal degeneration - More from this issue of Obesity and Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
